BYSI Stock Overview
A clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BeyondSpring Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.73 |
| 52 Week High | US$4.00 |
| 52 Week Low | US$0.78 |
| Beta | 0.30 |
| 11 Month Change | -30.68% |
| 3 Month Change | -7.70% |
| 1 Year Change | 84.80% |
| 33 Year Change | -87.04% |
| 5 Year Change | -87.64% |
| Change since IPO | -89.73% |
Recent News & Updates
Recent updates
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Jun 21
BeyondSpring, Beyond Salvage
Feb 03Circling Back On BeyondSpring
Nov 16Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk
Sep 07BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Aug 01BeyondSpring EPS misses by $0.04
Jun 16BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia
Jun 07FDA grants accelerated review to BeyondSpring's plinabulin combo application; shares up 8%
Jun 01BeyondSpring EPS misses by $0.17
Apr 30How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?
Dec 22
BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
Dec 15BeyondSpring slides 9% on public offering pricing at $10.0/share
Nov 19BeyondSpring under pressure on shares offering
Nov 17BeyondSpring's plinabulin combo meets primary endpoint in neutropenia trial
Nov 16Shareholder Returns
| BYSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.7% | -5.8% | -0.5% |
| 1Y | 84.8% | 20.8% | 32.3% |
Return vs Industry: BYSI exceeded the US Biotechs industry which returned 22.2% over the past year.
Return vs Market: BYSI exceeded the US Market which returned 33.1% over the past year.
Price Volatility
| BYSI volatility | |
|---|---|
| BYSI Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BYSI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BYSI's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 36 | Lan Huang | beyondspringpharma.com |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type.
BeyondSpring Inc. Fundamentals Summary
| BYSI fundamental statistics | |
|---|---|
| Market cap | US$74.56m |
| Earnings (TTM) | -US$15.57m |
| Revenue (TTM) | US$1.88m |
37.1x
P/S Ratio-4.5x
P/E RatioIs BYSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BYSI income statement (TTM) | |
|---|---|
| Revenue | US$1.88m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.88m |
| Other Expenses | US$17.44m |
| Earnings | -US$15.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -829.85% |
| Debt/Equity Ratio | 0% |
How did BYSI perform over the long term?
See historical performance and comparison